Dok-7: Difference between revisions
CSV import |
CSV import |
||
| Line 41: | Line 41: | ||
[[Category:Immunology]] | [[Category:Immunology]] | ||
[[Category:Genetic disorders]] | [[Category:Genetic disorders]] | ||
{{No image}} | |||
{{No image}} | {{No image}} | ||
Revision as of 15:49, 10 February 2025
Dock8
Dock8, also known as Dedicator of Cytokinesis 8, is a protein encoded by the DOCK8 gene in humans. This protein is a member of the DOCK family of guanine nucleotide exchange factors (GEFs) and plays a crucial role in the immune system, particularly in the function of T cells, B cells, and natural killer (NK) cells.
Structure and Function
Dock8 is a large protein that contains several domains essential for its function. It includes a DHR-1 (DOCK Homology Region 1) domain, which is involved in phospholipid binding, and a DHR-2 domain, which acts as a GEF for the small GTPase Cdc42. This activity is critical for the regulation of actin cytoskeleton dynamics, which is important for cell shape, migration, and immune synapse formation.
Role in the Immune System
Dock8 is predominantly expressed in hematopoietic cells and is essential for the proper functioning of the immune system. It is involved in the:
- Migration and adhesion of immune cells: Dock8 facilitates the movement of immune cells to sites of infection or inflammation by regulating the actin cytoskeleton.
- Immune synapse formation: It is crucial for the formation of the immune synapse, a specialized junction between T cells and antigen-presenting cells that is necessary for effective immune responses.
- Survival and proliferation of lymphocytes: Dock8 supports the survival and proliferation of T and B lymphocytes, which are vital for adaptive immunity.
Clinical Significance
Mutations in the DOCK8 gene are associated with a rare autosomal recessive disorder known as DOCK8 immunodeficiency syndrome. This condition is characterized by:
- Recurrent viral and bacterial infections: Due to impaired immune cell function.
- Severe eczema: A common skin manifestation in affected individuals.
- Increased risk of malignancies: Particularly lymphomas and other hematological cancers.
Patients with DOCK8 deficiency often present with a combination of immunodeficiency, allergy, and autoimmunity, making early diagnosis and management crucial.
Research and Therapeutic Approaches
Research into Dock8 and its associated pathways is ongoing, with the aim of developing targeted therapies for DOCK8 immunodeficiency syndrome. Current approaches include:
- Gene therapy: Efforts are being made to correct the genetic defect in affected individuals.
- Bone marrow transplantation: This has been used successfully in some cases to restore immune function.
Also see

This article is a immunology stub. You can help WikiMD by expanding it!
